OneDigital Investment Advisors LLC Has $4.38 Million Position in DexCom, Inc. (NASDAQ:DXCM)

OneDigital Investment Advisors LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 6.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,070 shares of the medical device company’s stock after acquiring an additional 3,798 shares during the period. OneDigital Investment Advisors LLC’s holdings in DexCom were worth $4,375,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Larson Financial Group LLC lifted its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the period. Nia Impact Advisors LLC increased its stake in shares of DexCom by 1.4% in the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company’s stock valued at $766,000 after acquiring an additional 140 shares in the last quarter. Level Four Advisory Services LLC lifted its position in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock valued at $1,026,000 after acquiring an additional 150 shares during the period. Covestor Ltd boosted its stake in DexCom by 15.6% during the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company’s stock worth $86,000 after acquiring an additional 150 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $82.73 on Friday. The company has a market capitalization of $32.44 billion, a PE ratio of 61.74, a PEG ratio of 1.77 and a beta of 1.44. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average price is $83.26 and its 200-day moving average price is $79.82. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 earnings per share. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In related news, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director owned 33,411 shares of the company’s stock, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock valued at $2,281,732 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DXCM. Barclays lifted their price target on shares of DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a research note on Monday, May 5th. Robert W. Baird dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Cfra Research raised DexCom to a “hold” rating in a research note on Friday, March 21st. Canaccord Genuity Group boosted their price objective on DexCom from $103.00 to $106.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.